HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

7- benzyl- 1- (3- (piperidin- 1- yl)propyl)- 2- (4- (pyridin- 4- yl)phenyl)- 1H- imidazo(4,5- g)quinoxalin- 6(5H)- one

inhibits interleukin-2-inducible T-cell kinase; structure in first source

Also Known As:

CTA056

Networked: 1 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Quinazolines: 402
      - 7-benzyl-1-(3-(piperidin-1-yl)propyl)-2-(4-(pyridin-4-yl)phenyl)-1H-imidazo(4,5-g)quinoxalin-6(5H)-one: 1
    - Benzimidazoles: 245
      - 7-benzyl-1-(3-(piperidin-1-yl)propyl)-2-(4-(pyridin-4-yl)phenyl)-1H-imidazo(4,5-g)quinoxalin-6(5H)-one: 1

Experts

1.	Guo, Wenchang: 1 article (11/2012)
2.	Huang, Wenzhe: 1 article (11/2012)
3.	Kung, Hsing-Jien: 1 article (11/2012)
4.	Lam, Kit S: 1 article (11/2012)
5.	Li, Jixian: 1 article (11/2012)
6.	Liu, Ruiwu: 1 article (11/2012)
7.	Ma, Ai-Hong: 1 article (11/2012)
8.	Martinez, Anthony: 1 article (11/2012)
9.	Maverakis, Emanual: 1 article (11/2012)
10.	Mazloom, Anisha: 1 article (11/2012)

Related Diseases

1.	Carcinogenesis 11/01/2012 - "The potent apoptosis-inducing potential of CTA056 is reflected by the significant modulation of microRNAs involved in survival pathways and oncogenesis. "
2.	Cutaneous T-Cell Lymphoma (Lymphoma, T Cell, Cutaneous) 11/01/2012 - "Among the 41 cancer cell lines analyzed, CTA056 selectively targets acute lymphoblastic T-cell leukemia and cutaneous T-cell lymphoma. "
3.	T-Cell Leukemia (Leukemia, T Cell) 11/01/2012 - "The selective expression and activation of Itk in malignant T cells, as well as the specificity of CTA056 for Itk, make this molecule a potential therapeutic agent for the treatment of T-cell leukemia and lymphoma." 11/01/2012 - "Among the 41 cancer cell lines analyzed, CTA056 selectively targets acute lymphoblastic T-cell leukemia and cutaneous T-cell lymphoma. "
4.	Neoplasms (Cancer) 11/01/2012 - "Among the 41 cancer cell lines analyzed, CTA056 selectively targets acute lymphoblastic T-cell leukemia and cutaneous T-cell lymphoma. "
5.	Lymphoma (Lymphomas) 11/01/2012 - "The selective expression and activation of Itk in malignant T cells, as well as the specificity of CTA056 for Itk, make this molecule a potential therapeutic agent for the treatment of T-cell leukemia and lymphoma."

Related Drugs and Biologics

1.	MicroRNAs (MicroRNA)